Clinical cancer research : an official journal of the American Association for Cancer Research

Prognostic biomarkers in head and neck cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research

Grandis JR

Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting.

Clinical cancer research : an official journal of the American Association for Cancer Research

Sok JC, Coppelli FM, Thomas SM, Lango MN, Xi S, Hunt JL, Freilino ML, Graner MW, Wikstrand CJ, Bigner DD, Gooding WE, Furnari FB, Grandis JR

Prognostic biomarkers in head and neck cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research

Grandis JR

Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting.

Clinical cancer research : an official journal of the American Association for Cancer Research

Sok JC, Coppelli FM, Thomas SM, Lango MN, Xi S, Hunt JL, Freilino ML, Graner MW, Wikstrand CJ, Bigner DD, Gooding WE, Furnari FB, Grandis JR

Targeting the double-strand DNA break repair pathway as a therapeutic strategy.

Clinical cancer research : an official journal of the American Association for Cancer Research

Lord CJ, Garrett MD, Ashworth A

Increased bioavailability of intravenous versus oral CI-1033, a pan erbB tyrosine kinase inhibitor: results of a phase I pharmacokinetic study.

Clinical cancer research : an official journal of the American Association for Cancer Research

Simon GR, Garrett CR, Olson SC, Langevin M, Eiseman IA, Mahany JJ, Williams CC, Lush R, Daud A, Munster P, Chiappori A, Fishman M, Bepler G, Lenehan PF, Sullivan DM

Targeting the double-strand DNA break repair pathway as a therapeutic strategy.

Clinical cancer research : an official journal of the American Association for Cancer Research

Lord CJ, Garrett MD, Ashworth A

Increased bioavailability of intravenous versus oral CI-1033, a pan erbB tyrosine kinase inhibitor: results of a phase I pharmacokinetic study.

Clinical cancer research : an official journal of the American Association for Cancer Research

Simon GR, Garrett CR, Olson SC, Langevin M, Eiseman IA, Mahany JJ, Williams CC, Lush R, Daud A, Munster P, Chiappori A, Fishman M, Bepler G, Lenehan PF, Sullivan DM

Epidermal growth factor receptor kinase domain mutations in esophageal and pancreatic adenocarcinomas.

Clinical cancer research : an official journal of the American Association for Cancer Research

Kwak EL, Jankowski J, Thayer SP, Lauwers GY, Brannigan BW, Harris PL, Okimoto RA, Haserlat SM, Driscoll DR, Ferry D, Muir B, Settleman J, Fuchs CS, Kulke MH, Ryan DP, Clark JW, Sgroi DC, Haber DA, Bell DW

Delta-24 increases the expression and activity of topoisomerase I and enhances the antiglioma effect of irinotecan.

Clinical cancer research : an official journal of the American Association for Cancer Research

Gomez-Manzano C, Alonso MM, Yung WK, McCormick F, Curiel DT, Lang FF, Jiang H, Bekele BN, Zhou X, Alemany R, Fueyo J

Pages